Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
All Other Types
OTHER TYPES OF CMT: STRATEGY Although there are more than 100 different genes that cause CMT, there are some common symptoms that affect people living with CMT such as axon…
Disability for CMT Peripheral Neuropathy: VA & Social Security
How likely are people with CMT to get Social Security disability benefits the first time they apply? Many people believe that it is very difficult to get disability benefits from…
Nervosave: Shaping the Future of Genetic Therapy for CMT1A
…is looking for: Individuals with genetically confirmed CMT1A Symptomatic individuals with a confirmed family history of CMT1A Parents of children with genetically confirmed CMT1A What’s Involved? Participation involves completing a…
CMTA-STAR Alliance Partner Begins Clinical Trial in CMT2S
…of CMT, including rare subtypes like CMT2S. We are proud to partner with CMTA-STAR Alliance Partner Vanda Pharmaceuticals as they advance this precision-driven program. CMTA Strategy to Accelerate Research (CMTA-STAR)…
CMTA and Pharnext Enter Biomarker Research Collaboration
…About CMTA The CMTA is aggressively leading the fight to fund the development of treatments and, ultimately, a cure for CMT. Through its Strategy to Accelerate Research (STAR), the CMTA…
CMTA Grassroots Events
At the CMTA, our vision is a world without CMT. Our mission is to support the development of new drugs to treat CMT, to improve the quality of life for…
CMTA Unveils Updated Logo
…20 pharmaceutical and biotechnology partners, the world’s top CMT scientists collaborating through STAR, and a community powering our efforts, the CMTA is leading the way to a world without CMT….
CMTA Appoints David Skarinsky to its Therapy Expert Board
…by Novartis), focusing on neuromuscular disease and CMT1A drug development. CMTA’s TEB, comprising top experts in CMT, provides scientific input, evaluates ongoing or proposed CMTA-funded research projects, and guides the…
CMTA and ToolGen Announce CMT1A Collaboration
CMTA and ToolGen Announce Collaboration to Develop Potential Treatment for CMT1A Using Gene Therapy (Glenolden, PA, October 7, 2021) The Charcot–Marie–Tooth Association (CMTA), the largest philanthropic funder of CMT research…
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
…designation (RPDD) designation from the FDA for ABS-0871, a TRPV4 inhibitor for treating CMT2C. This achievement represents a crucial step forward for CMT2C patients and the CMT community. “We are…